Coverage
12 companies
- Lead links
- 0
- Instruments
- Equity / unspecified
- Sourced relationships
- 12
- Distinct source URLs
- 27
- Crawl status
- Official page mapped
Sourced investor record
British Patient Capital
Fund and co-investment portfolio source
Portfolio links120 lead relationships
- Indexing state
- Evidence-qualified
- Latest dated link
- 2025-03-05
- Earliest dated link
- 2021-09-15
- Snapshot
- 2026-08-25
Official source
Portfolio located
Open official portfolio ↗Evidence ledger
12 retained relationships
A link records a disclosed or retained research relationship; it does not imply a current holding. Every row exposes the source layer, observation date, match method and publication state. Exact dated matches link onward to the funding record.
Observed roles
Evidence threshold
This page meets the retained indexing threshold through an official portfolio URL, three or more linked companies or two distinct relationship-source URLs.
12 relationships shown
| Company | Role | Round | Date | Named sources | Match / state |
|---|---|---|---|---|---|
| Quantexa | participant | Series F, Series E | 2025-03-05 | Quantexa ↗ · TechCrunch ↗ · Fintechfutures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Tokamak Energy | participant | Growth funding round (ambiguous stage — unlettered private round), Growth funding round (stage ambiguous - not formally labelled as a VC Series) | 2024-11-20 | Tokamakenergy ↗ · Axios ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Purespring Therapeutics | participant | Series B | 2024-10-01 | Globenewswire ↗ · Fiercebiotech ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Pragmatic Semiconductor | participant | Series D | 2023-12-01 | Pragmaticsemi ↗ · Wsgr ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| OMass Therapeutics | participant | Series B | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| CyberSmart | participant | Series B | 2023-02-01 | UKTN ↗ · Osborneclarke ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Grey Wolf Therapeutics | participant | Series B | 2023-01-01 | Sifted ↗ · Sifted ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| CloudNC | participant | Series B | 2022-06-21 | Tech.eu ↗ · Cloudnc ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Microbiotica | participant | Series B | 2022-03-07 | Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Paragraf | participant | Series B | 2022-03-01 | Paragraf ↗ · Moltenventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Ultraleap | participant | Series D | 2021-11-17 | PR Newswire ↗ · TechCrunch ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Accurx | participant | Series B | 2021-09-15 | Medium ↗ · Info ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Recent linked companies
12 of 12 observed companies
The most recently dated retained relationships are shown first; the complete sourced set remains in the ledger above.
QuantexaOpen company recordTokamak EnergyOpen company recordPurespring TherapeuticsOpen company recordPragmatic SemiconductorOpen company recordOMass TherapeuticsOpen company recordCyberSmartOpen company recordGrey Wolf TherapeuticsOpen company recordCloudNCOpen company recordMicrobioticaOpen company recordParagrafOpen company recordUltraleapOpen company recordAccurxOpen company record